share_log

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target

JMP Securities重申蓝图药物的市场表现跑赢大盘,维持114美元的目标股价
Moomoo 24/7 ·  04/10 11:02

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $114 price target.

JMP Securities分析师雷尼·本杰明重申蓝图药业(纳斯达克股票代码:BPMC)的市场表现优于大盘,并维持114美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发